AU2022422572A1 - Discernible cell surface protein variants of cd45 for use in cell therapy - Google Patents

Discernible cell surface protein variants of cd45 for use in cell therapy Download PDF

Info

Publication number
AU2022422572A1
AU2022422572A1 AU2022422572A AU2022422572A AU2022422572A1 AU 2022422572 A1 AU2022422572 A1 AU 2022422572A1 AU 2022422572 A AU2022422572 A AU 2022422572A AU 2022422572 A AU2022422572 A AU 2022422572A AU 2022422572 A1 AU2022422572 A1 AU 2022422572A1
Authority
AU
Australia
Prior art keywords
seq
cells
isoform
cell
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022422572A
Other languages
English (en)
Inventor
Anna CAMUS
Anna DEVAUX
Izabela DURZYNSKA
Simon GARAUDE
Anna HAYDN
Lukas JEKER
Rosalba LEPORE
Romina MATTER MARONE
Alessandro Sinopoli
Stefanie Urlinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cimeio Therapeutics Ag
Universitaet Basel
Original Assignee
Cimeio Therapeutics Ag
Universitaet Basel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cimeio Therapeutics Ag, Universitaet Basel filed Critical Cimeio Therapeutics Ag
Publication of AU2022422572A1 publication Critical patent/AU2022422572A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70589—CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022422572A 2021-12-23 2022-12-23 Discernible cell surface protein variants of cd45 for use in cell therapy Pending AU2022422572A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21217465 2021-12-23
EP21217465.0 2021-12-23
PCT/EP2022/087829 WO2023118608A1 (en) 2021-12-23 2022-12-23 Discernible cell surface protein variants of cd45 for use in cell therapy

Publications (1)

Publication Number Publication Date
AU2022422572A1 true AU2022422572A1 (en) 2024-06-06

Family

ID=79171049

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022422572A Pending AU2022422572A1 (en) 2021-12-23 2022-12-23 Discernible cell surface protein variants of cd45 for use in cell therapy

Country Status (10)

Country Link
EP (1) EP4452417A1 (https=)
JP (1) JP2025500288A (https=)
KR (1) KR20240119146A (https=)
CN (1) CN118541158A (https=)
AU (1) AU2022422572A1 (https=)
CA (1) CA3240875A1 (https=)
IL (1) IL313785A (https=)
MX (1) MX2024007316A (https=)
WO (1) WO2023118608A1 (https=)
ZA (1) ZA202405124B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
WO2026082736A1 (en) * 2024-10-14 2026-04-23 Cimeio Therapeutics Ag Chimeric antigen receptor (car) that targets receptor-type tyrosine phosphatase c (cd45) and its use to related applications

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170226209A1 (en) 2014-08-01 2017-08-10 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
WO2017155937A1 (en) 2016-03-07 2017-09-14 Actinium Pharmaceuticals, Inc. Stabilized radiolabeled anti-cd45 immunoglobulin compositions
US11499168B2 (en) 2016-04-25 2022-11-15 Universitat Basel Allele editing and applications thereof
CN109641051A (zh) 2016-06-17 2019-04-16 美真达治疗公司 用于耗尽细胞的组合物和方法
LT3535392T (lt) 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
RU2019130504A (ru) 2017-02-28 2021-03-30 Вор Байофарма, Инк. Композиции и способы ингибирования линиеспецифических белков
WO2019084273A1 (en) 2017-10-25 2019-05-02 Actinium Pharmaceuticals, Inc. METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
CN109991410B (zh) 2017-12-29 2022-07-05 上海白泽医学检验所有限公司 一种含抗cd45单抗的组合物及其使用方法
WO2020018580A1 (en) 2018-07-16 2020-01-23 Fred Hutchinson Cancer Research Center Bispecific affinity reagent and related methods for pretargeted radioimmunotherapy against cd45+ cell
EP3626265A1 (en) 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
EP3877416A4 (en) 2018-10-30 2022-07-27 Magenta Therapeutics, Inc. ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF
WO2020092655A1 (en) * 2018-10-30 2020-05-07 Magenta Therapeutics, Inc. Methods for allogeneic hematopoietic stem cell transplantation
WO2020159656A1 (en) 2019-02-01 2020-08-06 Actinium Pharmaceuticals, Inc. Molecules and their derivatives directed against cd45
WO2020170254A1 (en) 2019-02-21 2020-08-27 Ramot At Tel-Aviv University Ltd. Treatment of diseases with multimeric peptides

Also Published As

Publication number Publication date
WO2023118608A1 (en) 2023-06-29
CA3240875A1 (en) 2023-06-29
JP2025500288A (ja) 2025-01-09
EP4452417A1 (en) 2024-10-30
KR20240119146A (ko) 2024-08-06
MX2024007316A (es) 2024-06-26
CN118541158A (zh) 2024-08-23
ZA202405124B (en) 2025-10-29
IL313785A (en) 2024-08-01

Similar Documents

Publication Publication Date Title
JP7386082B2 (ja) 系統特異的タンパク質の阻害のための組成物および方法
JP6865688B2 (ja) Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
TWI825431B (zh) FcRH5之人源化及親和力成熟抗體及使用方法
CN103476429B (zh) 新型调节剂及使用方法
CN110066338B (zh) 作为T细胞衔接器的双特异性IgG抗体
JP7323102B2 (ja) 抗ｐｓｍａ抗体およびその使用
CN117616123B (zh) 抗ctla-4抗体
JP2020182454A (ja) Ｃｄ１９に特異的な抗体およびキメラ抗原受容体
WO2020212710A1 (en) Antagonists anti-cd7 antibodies
US20250057951A1 (en) Discernible cell surface protein variants of cd117 for use in cell therapy
CN117545779B (zh) 抗ctla-4抗体的用途
CN115397515A (zh) 人抗cd33抗体和其用途
US20240189424A1 (en) Engineered natural ligand-based car: directed evolution of the stress-receptor nkp30
AU2022422572A1 (en) Discernible cell surface protein variants of cd45 for use in cell therapy
US20250326818A1 (en) Discernible cell surface protein variants for use in cell therapy
WO2024208836A1 (en) Discernible cell surface protein variants of cd33 for use in cell therapy
JP7854975B2 (ja) 系統特異的タンパク質の阻害のための組成物および方法
CN118401558A (zh) 用于细胞疗法的cd117的可辨识细胞表面蛋白变体
WO2025031965A1 (en) Discernible cell surface protein variants of cd52 for use in cell therapy
CN117813110A (zh) 用于在细胞治疗中使用的可辨别细胞表面蛋白变体